Hansi Dean

Dr. Dean has more than twenty years experience in vaccine development and virology, including R&D management, product development and project management. She has developed and implemented vaccine project and portfolio management systems, and has led vaccine development projects in infectious disease and cancer. She has managed vaccine development collaborations with partners in twelve countries. Dr. Dean has scientific expertise in conventional and recombinant viral vaccines, DNA vaccines and vaccine formulations.

Dr. Dean has been consulting in biologics development since 2004, with a focus on international product development, technology evaluation, project management and regulatory, preclinical and clinical development strategy. She has assisted companies in evaluating technologies,writing business plans, securing funding for preclinical and clinical vaccine trials, and creating clinical development plans.

Dr. Dean is currently Director of New Alliances at International AIDS Vaccine Initiative, where she directs technology identification efforts geared toward addressing unmet needs in a portfolio of international collaborative HIV vaccine projects. Previously, Dr. Dean was Director of Program Management with PowderJect Vaccines, Inc. In that role, she managed a portfolio of preclinical and clinical projects to demonstrate clinical proof of concept in the areas of prophylactic and therapeutic vaccines for infectious diseases, cancer and allergy. She managed international vaccine development collaborations with biotech, government, and academic institutions. Her experience included coordination of preclinical development plans, clinical and regulatory strategy, clinical trial design, US and EU regulatory submissions, manufacturing transfer, portfolio strategic development, acquisition of grants and contracts, and business development.

Prior to joining PowderJect, Dr. Dean was Sr. Director, Infectious Disease and Drug Delivery at Endorex Corporation, a biotech start-up focused on mucosal protein and peptide delivery. She managed international collaborations with major pharmaceutical companies in infectious disease vaccines, allergy, and drug delivery. Prior to that, Dr. Dean headed the Viral Vaccine Development effort at Schering-Plough Animal Health, where she was responsible for viral vaccine new technology identification, research, development, licensing, and post-licensing support activities. In this role, Dr. Dean participated in product development and support for the US, Latin America, Japan and Europe. She developed and implemented strategies for maximizing value of a portfolio of vaccines through product improvements, line extensions, and new vaccine development, and led a team that licensed four multivalent vaccines.

Prior to her industry career, Dr. Dean conducted scientific research at the U.S. Department of Agriculture, where she worked in the areas of herpesvirus molecular virology and disease pathogenesis as part of a disease eradication program.

Dr. Dean received a Ph.D. in Microbiology and Immunology from Northwestern University Medical School, where she studied molecular virology, and a B.S. in Chemistry from the University of Michigan. She is co-author of numerous scientific publications in the areas of vaccine development and molecular virology. In addition, she has presented scientific and product development seminars at international scientific meetings, professional conferences, universities, and government laboratories.